SCHEMBL1542824

SCHEMBL1542824

COc1c(C(=O)Nc2ccccc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.52
NR1H4 Q96RI1 2/20 0.45
HTT P42858 1/20 0.44
ABL1 P00519 1/20 0.43
GAA P10253 3/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
BLM P54132 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
TYK2 P29597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127583 0.89 CYP3A4 (0.50) CYP3A4NR1H4ABL1KDM4EKMT2A
SCHEMBL1542874 0.88 CYP3A4 (0.51) CYP3A4NR1H4HTTABL1GAA
SCHEMBL2128285 0.87 KDM4E (0.49) CYP3A4NR1H4HTTKDM4EKMT2A
SCHEMBL1542683 0.87 CYP3A4 (0.61) CYP3A4NR1H4ABL1GAAKDM4E
SCHEMBL1542666 0.86 CYP3A4 (0.56) CYP3A4NR1H4HTTABL1GAA
SCHEMBL1542187 0.85 CYP3A4 (0.49) CYP3A4NR1H4HTTABL1GAA
SCHEMBL2128170 0.85 CYP3A4 (0.53) CYP3A4NR1H4HTTABL1KDM4E
SCHEMBL1542439 0.85 CYP3A4 (0.51) CYP3A4KDM4EPOLBKMT2AMEN1
SCHEMBL1543035 0.85 CYP3A4 (0.61) CYP3A4NR1H4ABL1GAAKDM4E
SCHEMBL1542980 0.84 CYP3A4 (0.49) CYP3A4HTTABL1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885NR1H4 658/4885HTT 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.